BCDA Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

BioCardia Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerBCDA

Market Cap10.7M

Cash RunwayRunway < 6 months

Next Catalyst2026-12

Public Research Snapshot

BioCardia Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Autologous cell therapy in Heart Failure, Systolic (Phase 3) using Cell Therapy.

Pipeline

Asset	Indication	Modality	Stage	Public Note
ABOUT US	n/a	Cell Therapy	n/a	Public pipeline row
Recent Events	Favorable Cell Characteristics - Late Breaking Echocardiography Results	Cell Therapy	n/a	Public pipeline row
BCDA-03	n/a	n/a	Phase 1/2	Public pipeline row
BCDA-01	Ischemic Heart Failure BCDA-01/ NCT02438306 and NCT06258447	Cell Therapy	n/a	Public pipeline row
CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)	Heart Failure, Systolic	n/a	Phase 1 \| Phase 2	Public pipeline row
Autologous cell therapy	Heart Failure, Systolic	Cell Therapy	Phase 3	Public pipeline row
CardiAMP Cell Therapy System	Refractory Angina \| Chronic Myocardial Ischemia	Cell Therapy	Na	Public pipeline row
JVS-100 15 mg dose Injection	Ischemic Heart Failure	n/a	Phase 2	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2026-12	CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)	Low
		Corporate Update	Q4 2026	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT00507468	Phase 1	COMPLETED	20	2009-03
NCT01643590	Phase 2	UNKNOWN	90	2014-10
NCT02438306	Phase 3	COMPLETED	125	2025-02
NCT03455725	Na	ACTIVE_NOT_RECRUITING	343	2025-02-19
NCT05925608	Phase 1 \| Phase 2	ACTIVE_NOT_RECRUITING	39	2026-12

Scientific Context

catalyst_type | Corporate Update
catalyst_window | Q4 2026
asset_name | ABOUT US
indication | the treatment of unmet cardiovascular and pulmonary diseases
modality | Cell Therapy

Want the full BCDA research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.